改变血友病护理:新兴的治疗创新和挑战
1The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Expert review of hematology
|June 28, 2025
概括
创新的血友病疗法提供了更好的结果和更好的生活质量. 延长半衰期因子,非因子治疗和基因疗法正在改变对血友病A和B患者的护理.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 血友病A和B是慢性出血障碍,可以通过因子替代治疗来治疗.
- 目前的治疗方法面临诸如频繁注射,抑制剂开发和高成本等挑战.
研究的目的:
- 审查最近在血友病管理方面的进展.
- 探索新的治疗策略及其临床影响.
主要方法:
- 在PubMed,Embase,Web of Science和ClinicalTrials.gov (2014年1月至2025年4月) 的综合文献搜索.
- 包括关键的临床试验,现实世界的数据和翻译研究.
主要成果:
- 延长半衰期因子缩剂提供了简化剂量.
- 非因子疗法 (双特异性抗体,再平衡剂) 是有前途的,特别是对于抑制剂患者.
- 基因疗法提供了潜在的功能疗法,但需要进一步研究耐用性和安全性.
结论:
- 新型疗法正在改善血友病护理,提供更好的出血控制和方便.
- 基因疗法具有显著的潜力,但在长期有效性,免疫性和成本方面面临挑战.
- 个性化治疗和持续的研究对于推进血友病管理和改善患者生活至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
27
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
27
Anticoagulant Drugs: Low-Molecular-Weight Heparins
921
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
921
Issues And Trends In Healthcare Delivery System
5.9K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.9K
Microorganisms in Medicine and Therapeutics
360
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
360
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


